PDCD1 and neoplasm: A phase II clinical trial is determining the efficacy of TSR-022, as an anti-TIM-3 antibody in combination with TSR-042 (anti-PD-1 antibody) in eradicating tumor cells in advanced or metastatic liver cancer (NCT03680508).